We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bionano Genomics Inc | NASDAQ:BNGO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 5.26% | 1.00 | 0.9905 | 1.00 | 1.01 | 0.95 | 0.95 | 839,780 | 00:27:03 |
•
|
the size and growth potential of the markets for our products, and our ability to serve those markets;
|
•
|
the impact of the COVID-19 pandemic on our business and operations;
|
•
|
the rate and degree of market acceptance of our products;
|
•
|
ability to expand our sales organization to address effectively existing and new markets that we intend to target;
|
•
|
impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries;
|
•
|
ability to compete effectively in a competitive industry;
|
•
|
the success of competing technologies that are or may become available;
|
•
|
the performance of our third-party contract sales organizations, suppliers and manufacturers;
|
•
|
our ability to attract and retain key scientific or management personnel;
|
•
|
the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing;
|
•
|
our ability to comply with the covenants and satisfy certain conditions of our debt facility;
|
•
|
our ability to obtain funding for our operations; and
|
•
|
our ability to attract collaborators and strategic partnerships.
|
•
|
Get the Service. Customers can submit samples to Bionano Data Services and receive an appropriately filtered set of structural variant calls. Structural variation data is then presented using the Bionano Access visualization software, and files can be exported in the format of choice. Pricing for this service is $650 per genome for standard samples and $750 per genome for mosaic and cancer samples.
|
•
|
Get the Consumables. For customers who commit to purchase at least 120 genomes every six months, the Bionano Support team will install the Saphyr System on the customer’s premises and provide training on sample preparation, instrument operation and data analysis. Pricing for this service is $550 per genome, with installation and training included at no cost, and the Saphyr instrument made available at no charge for the duration of the customer’s project.
|
•
|
Get the Saphyr System. For customers who purchase the Saphyr System, the Bionano Support team will install the Saphyr System and provide training on sample preparation, instrument operation and data analysis. Pricing begins at $150,000 for the Saphyr instrument, $550 per genome or $450 per genome with a 240 genome bundle, with installation and training included at no cost.
|
|
| |
Before Offering
|
| |
|
| |
After Offering
|
||||||
Name and Address(1)
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage
of Shares Beneficially Owned |
| |
Number of
Shares to be Registered |
| |
Number of
Shares Beneficially Owned |
| |
Percentage
of Shares Beneficially Owned |
Innovatus Capital Partners LLC and Related Parties(2)
|
| |
2,764,009(3)
|
| |
3.3%
|
| |
872,601(4)
|
| |
1,891,408(3)
|
| |
2.2%
|
(1)
|
If required, information about other selling stockholders, except for any future transferees, pledgees, donees or successors of the selling stockholders named in the table above, will be set forth in a prospectus supplement or amendment to the registration statement of which this prospectus is a part. Additionally, post-effective amendments to the registration statement will be filed to disclose any material changes to the plan of distribution from the description contained in this prospectus.
|
(2)
|
Innovatus Capital Partners LLC, or Innovatus Manager, serves as investment manager to each of Innovatus and Innovatus Life Sciences Offshore Fund I-A, LP, or Innovatus Offshore. Innovatus Life Sciences GP, LP, or Innovatus GP, is the general partner of Innovatus. Innovatus Life Sciences Offshore GP, LP, or Innovatus Offshore GP, is the general partner of Innovatus Offshore. Each of Innovatus Manager, Innovatus, Innovatus GP, Innovatus Offshore and Innovatus Offshore GP are collectively referred to as the Innovatus Entities. Innovatus Flagship Parent GP, LLC, or Innovatus Holdings, is the parent company of Innovatus GP and Innovatus Offshore Parent GP, LLC, or Innovatus Offshore Holdings. David Schiff, a citizen of the United States, is the principal shareholder of each of Innovatus Holdings and Innovatus Offshore Holdings, collectively referred to as the Parent Entities, and could be deemed to exercise voting and investment power over the Parent Entities and the Innovatus Entities. The address of the principal place of business for each of the Innovatus Entities, the Parent Entities and David Schiff is 777 Third Avenue, 25th Floor, New York, NY 10017.
|
(3)
|
As of the date of this prospectus, includes an aggregate of (i) 341,856 shares of common stock issuable upon the exercise of outstanding warrants held by Innovatus and (ii) 195,131 shares of common stock issuable upon exercise of outstanding warrants held by Innovatus Offshore.
|
(4)
|
As of the date of this prospectus, consists of (i) 579,246 shares of common stock held by Innovatus Offshore and (ii) 293,355 shares of common stock held by Innovatus, which shares may be sold by any selling stockholder named in footnote (2) above, as future transferees, pledgees, donees or successors of such shares.
|
•
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
•
|
block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
|
•
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its own account;
|
•
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
•
|
privately negotiated transactions;
|
•
|
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
•
|
through agreements between broker-dealers and the selling stockholders to sell a specified number of such shares at a stipulated price per share;
|
•
|
a combination of any such methods of sale; and
|
•
|
any other method permitted by applicable law.
|
•
|
our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 10, 2020;
|
•
|
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC on June 18, 2020;
|
•
|
our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on January 30, 2020, March 2, 2020, April 6, 2020, April 20, 2020, April 24, 2020, May 5, 2020, May 14, 2020, June 19, 2020 and July 2, 2020; and
|
•
|
the description of our common stock which is registered under Section 12 of the Exchange Act, in our registration statement on Form 8-A, filed on August 17, 2018, including any amendment or reports filed for the purposes of updating this description.
|
1 Year Bionano Genomics Chart |
1 Month Bionano Genomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions